Olstein Capital Management L.P. Buys 5,000 Shares of Hologic, Inc. (NASDAQ:HOLX)

Olstein Capital Management L.P. boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 90,000 shares of the medical equipment provider’s stock after buying an additional 5,000 shares during the quarter. Olstein Capital Management L.P.’s holdings in Hologic were worth $6,488,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Public Sector Pension Investment Board raised its holdings in shares of Hologic by 92.5% in the 2nd quarter. Public Sector Pension Investment Board now owns 8,759 shares of the medical equipment provider’s stock valued at $650,000 after purchasing an additional 4,208 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in Hologic by 56.9% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 44,963 shares of the medical equipment provider’s stock valued at $3,339,000 after buying an additional 16,307 shares during the period. Squarepoint Ops LLC lifted its position in shares of Hologic by 251.9% in the second quarter. Squarepoint Ops LLC now owns 58,880 shares of the medical equipment provider’s stock valued at $4,372,000 after buying an additional 97,634 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Hologic by 1.5% during the 2nd quarter. AQR Capital Management LLC now owns 565,955 shares of the medical equipment provider’s stock worth $42,022,000 after acquiring an additional 8,441 shares during the period. Finally, APG Asset Management N.V. increased its holdings in shares of Hologic by 2.2% during the 2nd quarter. APG Asset Management N.V. now owns 360,093 shares of the medical equipment provider’s stock worth $24,947,000 after acquiring an additional 7,828 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

HOLX opened at $71.02 on Friday. The firm has a market cap of $16.03 billion, a P/E ratio of 21.33, a price-to-earnings-growth ratio of 2.43 and a beta of 0.97. The business’s fifty day moving average is $74.01 and its 200-day moving average is $78.25. Hologic, Inc. has a 52-week low of $68.61 and a 52-week high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.89 earnings per share. Sell-side analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.88% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have issued reports on HOLX. Evercore ISI raised their price target on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Wolfe Research started coverage on shares of Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and lowered their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Leerink Partners reduced their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Morgan Stanley lowered their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Seven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.